gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1087Research ArticleГЕПАТОЛОГИЯHEPATOLOGYЛекарственные поражения печениDrug-induced liver injuriesГалимоваС. Ф.GalimovaS. F.

Галимова Саида Фаритовна – кандидат медицинских наук, врач клиники пропедевтики внутренних болезней, гастроэнтерологии и гепатологии им. В.Х. Василенко

119991, Москва, ул. Погодинская, д. 1 стр. 1

Galimova Saida F. – MD, Vasilenko Clinic of internal diseases propedeutics, gastroenterology and hepatology

119991, Moscow, str. Pogodinskaya, 1, bld 1

ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава РФРоссияState educational government-financed institution of higher professional education «Sechenov First Moscow State Medical University» Ministry of Health and Social Development of RussiaRussian Federation2014150720142412128Copyright © Галимова С.Ф., 20142014Галимова С.Ф.Galimova S.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1087

Цель обзора. Осветить современные представления о ведении и мерах профилактики у пациентов с лекарственными поражениями печени (ЛПП).Основные положения. ЛПП имеют широкий спектр клинических проявлений, от бессимптомного повышения активности сывороточных трансаминаз до фульминантной печеночной недостаточности. Задача клинициста – своевременно отменить «причинный» препарат и по показаниям назначить специфическую и/или симптоматическую терапию. Меры профилактики включают глобальный контроль за проведением клинических и постмаркетинговых исследований. В основе профилактических мероприятий относительно конкретного пациента лежит соблюдение режима приема препарата, анализ факторов риска, полипрагмазии, лекарственных взаимодействий, проведение надлежащего обследования пациента при назначении средств, обладающих потенциальным гепатотоксическим действием.

The aim of review

The aim of review. To demonstrate modern concept on management and prevention in patients with drug-induced liver injury (DILI).

Key points

Key points. DILI have a wide spectrum of clinical symptoms, from asymptomatic elevation of serum transaminase activity to fulminant liver failure. The task of clinician – to withdraw a «causative» drug and under indications to prescribe specific and/or symptomatic treatment in due time. Preventive measures include global control of clinical and postmarketing investigations. Observation of mode of intake of the drug, analysis of risk factors, polypragmasy, drug interactions, carrying out of appropriate investigation at prescription of potentially hepatotoxic drugs lays at the basis of prevention concerning the specific patient.

лекарственное поражение печенипрофилактикаведение пациентарекомендацииdrug-induced liver injurypreventionmanagement of the patientguidelinesReferencesБолезни печени и желчевыводящих путей: Руководство для врачей / Под ред. В. Т. Ивашкина. – М.: Изд. Дом «М-Вести», 2005. – 217 с.Болезни печени и желчевыводящих путей: Руководство для врачей / Под ред. В. Т. Ивашкина. – М.: Изд. Дом «М-Вести», 2005. – 217 с.Ивашкин В. Т., Буеверов А. О. Патогенетическое и клиническое обоснование применения адеметионина в лечении больных с внутрипеченочным холестазом // Клин. перспективы гастроэнтерол. гепатол. – 2009. – № 5. – С. 24–29.Ивашкин В. Т., Буеверов А. О. Патогенетическое и клиническое обоснование применения адеметионина в лечении больных с внутрипеченочным холестазом // Клин. перспективы гастроэнтерол. гепатол. – 2009. – № 5. – С. 24–29.Рациональная фармакотерапия заболеваний органов пищеварения / Под общ. ред. В. Т. Ивашкина. – 2-е изд., испр. и доп. – М.: Литтерра, 2011. – 424 с.Рациональная фармакотерапия заболеваний органов пищеварения / Под общ. ред. В. Т. Ивашкина. – 2-е изд., испр. и доп. – М.: Литтерра, 2011. – 424 с.Algren D. A. Review of N-acetylcysteine for the treatment of acetaminofen (paracetamol) toxicity in pediatrics // Second meeting of the subcommittee of the expert committee on the selection and use of essential medicines, Geneva, 29.09–3.10.2008.Algren D. A. Review of N-acetylcysteine for the treatment of acetaminofen (paracetamol) toxicity in pediatrics // Second meeting of the subcommittee of the expert committee on the selection and use of essential medicines, Geneva, 29.09–3.10.2008.Andrade R. J., Lucena M. I. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period // Gastroenterology. – 2005. – Vol. 129, N 2. – P. 512–521.Andrade R. J., Lucena M. I. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period // Gastroenterology. – 2005. – Vol. 129, N 2. – P. 512–521.Bjornsson E., Olsson R. Suspected drug-induced liver fatalities reported to the WHO database // Dig. Liver Dis. – 2006. – N 38. – P. 33–38.Bjornsson E., Olsson R. Suspected drug-induced liver fatalities reported to the WHO database // Dig. Liver Dis. – 2006. – N 38. – P. 33–38.Bohan T. P., Helton E., McDonald I. et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity // Neurology. – 2001. – N 56. – P. 1405–1409.Bohan T. P., Helton E., McDonald I. et al. Effect of L-carnitine treatment for valproate-induced hepatotoxicity // Neurology. – 2001. – N 56. – P. 1405–1409.Chitturi S., Farrell G. C. Drug-induced liver disease // Schiff E. R. Schiff’s diseases of the liver, 9th ed. – Tokyo: Lippincott Williams & Wilkins, 2003. – P. 1059–1127.Chitturi S., Farrell G. C. Drug-induced liver disease // Schiff E. R. Schiff’s diseases of the liver, 9th ed. – Tokyo: Lippincott Williams & Wilkins, 2003. – P. 1059–1127.Cicognani C., Malavolti M. et al. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis // Dig. Dis. Sci. – 1996. – Vol. 41, N 11. – P. 2219–2221.Cicognani C., Malavolti M. et al. Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis // Dig. Dis. Sci. – 1996. – Vol. 41, N 11. – P. 2219–2221.Denise M. H. Use of Ursodeoxycholic acid therapy in the treatment of cholestatic liver diseases // US Gastroenterology review. – 2007. – P. 46–49.Denise M. H. Use of Ursodeoxycholic acid therapy in the treatment of cholestatic liver diseases // US Gastroenterology review. – 2007. – P. 46–49.Harrison P. M., Keays R. et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine // Lancet. – 1990. – N 335. – P. 1572–1573.Harrison P. M., Keays R. et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine // Lancet. – 1990. – N 335. – P. 1572–1573.Kagan B. L., Sultzer D. L. et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebocontrolled trial // Am. J. Psychiatry. – Vol. 147, N 5.– P. 591–595.Kagan B. L., Sultzer D. L. et al. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebocontrolled trial // Am. J. Psychiatry. – Vol. 147, N 5.– P. 591–595.Kaplowitz N., de Leve L. D. Drug-induced liver disease, 1sted. – New York: Informa Healthcare, 2003. – P. 227–242.Kaplowitz N., de Leve L. D. Drug-induced liver disease, 1sted. – New York: Informa Healthcare, 2003. – P. 227–242.Kazuto T., Yukihiro S. Practical guidelines for diagnosis and early management of drug-induced liver injury // World J Gastroenterol. – 2008. – Vol. 14, N 44. – P. 6774–6785.Kazuto T., Yukihiro S. Practical guidelines for diagnosis and early management of drug-induced liver injury // World J Gastroenterol. – 2008. – Vol. 14, N 44. – P. 6774–6785.Keays R., Harrison P. M. et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial // BMJ. – 1991. – N 303. – P. 1009–1026.Keays R., Harrison P. M. et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial // BMJ. – 1991. – N 303. – P. 1009–1026.Lheureux P., Penaloza А. et al. Science review: Carnitine in the treatment of valproic acid-induced toxicity – what is the evidence? // Crit. Care. – 2005. – Vol. 9, N 5. – P. 431–440.Lheureux P., Penaloza А. et al. Science review: Carnitine in the treatment of valproic acid-induced toxicity – what is the evidence? // Crit. Care. – 2005. – Vol. 9, N 5. – P. 431–440.LoVecchio F., Shriki J. et al. L-carnitine was safely administered in the setting of valproate toxicity. // Am. J. Emerg. Med. – 2005. – Vol. 23, N 3. – P. 321–322.LoVecchio F., Shriki J. et al. L-carnitine was safely administered in the setting of valproate toxicity. // Am. J. Emerg. Med. – 2005. – Vol. 23, N 3. – P. 321–322.Martinez-Chantar M.L., Garsia-Trevijano E.R. et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of the liver injury // Am. J. Clin. Nutr. – 2002. – Vol. 76, N 5. – P.1177–1182.Martinez-Chantar M.L., Garsia-Trevijano E.R. et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of the liver injury // Am. J. Clin. Nutr. – 2002. – Vol. 76, N 5. – P.1177–1182.Mato J., Camara J. et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial // J. Hepatology. – 1999. – N 30. – P.1081–1089.Mato J., Camara J. et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial // J. Hepatology. – 1999. – N 30. – P.1081–1089.Mulrow С., Lawrence V. Milk thistle: Effects on liver disease and cirrhosis and clinical adverse effects. Agency for healthcare research and quality evidence report // Techn. Assessment. – 2000. – N 21. – P. 1–9.Mulrow С., Lawrence V. Milk thistle: Effects on liver disease and cirrhosis and clinical adverse effects. Agency for healthcare research and quality evidence report // Techn. Assessment. – 2000. – N 21. – P. 1–9.Navarro V., John R. Drug-related hepatotoxicity // N. Engl. J. Med. – 2006 – Vol. 354. N 7. – P. 731–739.Navarro V., John R. Drug-related hepatotoxicity // N. Engl. J. Med. – 2006 – Vol. 354. N 7. – P. 731–739.Norris W., Paredes A. H., Lewis J. H. Drug-induced liver injury in 2007 // Curr. Opin. Gastroenterol. – 2008. – Vol. 24. – P. 287–297.Norris W., Paredes A. H., Lewis J. H. Drug-induced liver injury in 2007 // Curr. Opin. Gastroenterol. – 2008. – Vol. 24. – P. 287–297.Palazzi C., D’Amico E. et al. Normalization of methotrexate-induced high levels of serum transaminases after ursodeoxycholic acid administration in a rheumatoid arthritis patient // Rheumatology. – 2003. – Vol. 42, N 10. – P. 1266–1267.Palazzi C., D’Amico E. et al. Normalization of methotrexate-induced high levels of serum transaminases after ursodeoxycholic acid administration in a rheumatoid arthritis patient // Rheumatology. – 2003. – Vol. 42, N 10. – P. 1266–1267.Paumgartner G., Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease // Clin. Liver Dis. – 2004. – Vol. 8, N 1. – P. 67– 81.Paumgartner G., Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease // Clin. Liver Dis. – 2004. – Vol. 8, N 1. – P. 67– 81.Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited // Hepatology. – 2002. – Vol. 36, N 3. – P. 525–531.Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited // Hepatology. – 2002. – Vol. 36, N 3. – P. 525–531.Polson J., Lee W. M. AASLD position paper: the management of acute liver failure // Hepatology. – 2005. – Vol. 41, N 5. – P. 1179–1197.Polson J., Lee W. M. AASLD position paper: the management of acute liver failure // Hepatology. – 2005. – Vol. 41, N 5. – P. 1179–1197.Richard C. D., Andrew R. E. Practice guideline: Acetaminophen poisoning: An evidence-based consensus guideline for out-of-hospital management // Clin. Toxicol. – 2006. – Vol. 44, N 1. – P. 1–18.Richard C. D., Andrew R. E. Practice guideline: Acetaminophen poisoning: An evidence-based consensus guideline for out-of-hospital management // Clin. Toxicol. – 2006. – Vol. 44, N 1. – P. 1–18.Song Z., McClain C.J. et al. S-Adenosylmethionine protects against acetaminophen-induced hepatotoxicity in mice // Pharmacology. – 2004 – Vol. 71, N 4. – P. 199–208.Song Z., McClain C.J. et al. S-Adenosylmethionine protects against acetaminophen-induced hepatotoxicity in mice // Pharmacology. – 2004 – Vol. 71, N 4. – P. 199–208.Steiber A., Kerner J. et al. Carnitine: a nutritional, biosynthetic, and functional perspective // Mol. Aspects Med. – 2004. – Vol. 25, N 5–6. – P. 455–473.Steiber A., Kerner J. et al. Carnitine: a nutritional, biosynthetic, and functional perspective // Mol. Aspects Med. – 2004. – Vol. 25, N 5–6. – P. 455–473.Tisdale J. E., Miller D. A. Drug-induced diseases: prevention, detection, and management. 2nd ed. – Am. Soc. of Helth-System Pharm, 2010. – P. 771–796.Tisdale J. E., Miller D. A. Drug-induced diseases: prevention, detection, and management. 2nd ed. – Am. Soc. of Helth-System Pharm, 2010. – P. 771–796.Van Ede A. E., Laan R. F. et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study // Arthritis Rheum. – 2001. – Vol. 44, N 7. – P. 1515–1524.Van Ede A. E., Laan R. F. et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study // Arthritis Rheum. – 2001. – Vol. 44, N 7. – P. 1515–1524.Watkins P. B., Zimmerman H. J. et al .Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease // JAMA. – 1994. – N 271. – P. 992–998.Watkins P. B., Zimmerman H. J. et al .Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease // JAMA. – 1994. – N 271. – P. 992–998.William M. Lee. Drug-induced hepatotoxicity // N. Engl. J. Med. – 2003. – Vol. 349, N 5. – P. 474–485.William M. Lee. Drug-induced hepatotoxicity // N. Engl. J. Med. – 2003. – Vol. 349, N 5. – P. 474–485.Zimmerman H. J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. – New York: Appleton-Century-Crofts, 1978. – P. 349–369.Zimmerman H. J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. – New York: Appleton-Century-Crofts, 1978. – P. 349–369.Zimmerman H. J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. 2nd ed. – Philadelphia: Lippincott Williams & Wilkins, 1999. – P. 428–433.Zimmerman H. J. Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver. 2nd ed. – Philadelphia: Lippincott Williams & Wilkins, 1999. – P. 428–433.

The authors declare that there are no conflicts of interest present.